WallStreetZenWallStreetZen

NASDAQ: ABVX
Abivax Sa Stock Forecast, Predictions & Price Target

Analyst price target for ABVX

Based on 4 analysts offering 12 month price targets for Abivax Sa.
Min Forecast
$16.00+10.88%
Avg Forecast
$37.75+161.61%
Max Forecast
$50.00+246.5%

Should I buy or sell ABVX stock?

Based on 4 analysts offering ratings for Abivax Sa.
Strong Buy
Strong Buy
3 analysts 75%
Buy
0 analysts 0%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ABVX stock forecasts and price targets.

ABVX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-20
lockedlocked$00.00+00.00%2024-04-29
lockedlocked$00.00+00.00%2024-04-29
lockedlocked$00.00+00.00%2024-04-11

1 of 1

Forecast return on equity

Is ABVX forecast to generate an efficient return?
Company
-58.19%
Industry
76.1%
Market
79%
ABVX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ABVX forecast to generate an efficient return on assets?
Company
-34.87%
Industry
30.96%
ABVX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ABVX earnings per share forecast

What is ABVX's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$2.98
Avg 2 year Forecast
-$2.90
Avg 3 year Forecast
-$2.90

ABVX revenue forecast

What is ABVX's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$5.0M-3.59%
Avg 2 year Forecast
$5.0M-2.95%
Avg 3 year Forecast
$6.5M+27.49%
ABVX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ABVX revenue growth forecast

How is ABVX forecast to perform vs Biotechnology companies and vs the US market?
Company
7.79%
Industry
35%
Market
9.85%
ABVX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ABVX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ABVX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ABVX$14.43$37.75+161.61%Strong Buy
GYRE$10.62N/AN/A
SLN$20.80$57.25+175.24%Strong Buy
SAVA$19.07$131.00+586.94%Buy
STOK$17.19$21.40+24.49%Buy

Abivax Sa Stock Forecast FAQ

Is Abivax Sa Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: ABVX) stock is to Strong Buy ABVX stock.

Out of 4 analysts, 3 (75%) are recommending ABVX as a Strong Buy, 0 (0%) are recommending ABVX as a Buy, 1 (25%) are recommending ABVX as a Hold, 0 (0%) are recommending ABVX as a Sell, and 0 (0%) are recommending ABVX as a Strong Sell.

If you're new to stock investing, here's how to buy Abivax Sa stock.

What is ABVX's earnings growth forecast for 2024-2026?

(NASDAQ: ABVX) Abivax Sa's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.61%.

Abivax Sa's earnings in 2024 is -$160,586,956.On average, 3 Wall Street analysts forecast ABVX's earnings for 2024 to be -$187,735,543, with the lowest ABVX earnings forecast at -$210,811,540, and the highest ABVX earnings forecast at -$152,287,740. On average, 3 Wall Street analysts forecast ABVX's earnings for 2025 to be -$182,701,237, with the lowest ABVX earnings forecast at -$212,699,405, and the highest ABVX earnings forecast at -$165,502,791.

In 2026, ABVX is forecast to generate -$182,285,907 in earnings, with the lowest earnings forecast at -$218,992,287 and the highest earnings forecast at -$152,287,740.

What is ABVX's revenue growth forecast for 2024-2026?

(NASDAQ: ABVX) Abivax Sa's forecast annual revenue growth rate of 7.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.

Abivax Sa's revenue in 2024 is $5,022,826.On average, 3 Wall Street analysts forecast ABVX's revenue for 2024 to be $311,497,649, with the lowest ABVX revenue forecast at $302,687,615, and the highest ABVX revenue forecast at $317,790,531. On average, 3 Wall Street analysts forecast ABVX's revenue for 2025 to be $313,574,300, with the lowest ABVX revenue forecast at $302,687,615, and the highest ABVX revenue forecast at $324,083,413.

In 2026, ABVX is forecast to generate $411,932,043 in revenue, with the lowest revenue forecast at $302,687,615 and the highest revenue forecast at $619,219,569.

What is ABVX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ABVX) forecast ROA is -34.87%, which is lower than the forecast US Biotechnology industry average of 30.96%.

What is ABVX's Price Target?

According to 4 Wall Street analysts that have issued a 1 year ABVX price target, the average ABVX price target is $37.75, with the highest ABVX stock price forecast at $50.00 and the lowest ABVX stock price forecast at $16.00.

On average, Wall Street analysts predict that Abivax Sa's share price could reach $37.75 by May 20, 2025. The average Abivax Sa stock price prediction forecasts a potential upside of 161.61% from the current ABVX share price of $14.43.

What is ABVX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: ABVX) Abivax Sa's current Earnings Per Share (EPS) is -$3.73. On average, analysts forecast that ABVX's EPS will be -$2.98 for 2024, with the lowest EPS forecast at -$3.35, and the highest EPS forecast at -$2.42. On average, analysts forecast that ABVX's EPS will be -$2.90 for 2025, with the lowest EPS forecast at -$3.38, and the highest EPS forecast at -$2.63. In 2026, ABVX's EPS is forecast to hit -$2.90 (min: -$3.48, max: -$2.42).

What is ABVX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ABVX) forecast ROE is -58.19%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.